上海优宁维生物科技股份有限公司代理商

19

手机商铺

qrcode
商家活跃:
产品热度:
  • NaN
  • 0
  • 0
  • 2
  • 2
代理商

上海优宁维生物科技股份有限公司

入驻年限:19

  • 联系人:

    上海总部

  • 所在地区:

    上海 浦东新区

  • 业务范围:

    试剂

  • 经营模式:

    代理商

在线沟通

公司新闻/正文

BioXcell特色产品推荐之:InVivoMAb anti-mouse TNFα

345 人阅读发布时间:2022-04-18 14:49

一  产品介绍
TNFα以可溶性17 kDa单体存在,在循环中形成同源三聚体或以26 kDa膜结合形式存在。TNFα属于细胞因子的TNF超家族,并通过其两种受体TNFR1和TNFR2发出信号,这两种受体可被TNFα的可溶性三聚体和膜结合形式激活。TNFα主要由巨噬细胞在对外来抗原如细菌(脂多糖)、病毒和寄生虫以及有丝分裂原和其他细胞因子的反应中产生,但也可由单核细胞、嗜中性粒细胞、NK细胞、CD4 T细胞和一些特化树突细胞表达。已知TNFα在广泛的生物学过程中起关键作用,包括免疫调节、细胞增殖、分化、凋亡、抗肿瘤活性、炎症、厌食、恶病质、脓毒性休克、造血和病毒复制。TNFα失调与多种疾病有关,包括自身免疫性疾病、胰岛素抵抗和癌症。小鼠和人TNFα共享79%的氨基酸序列同一性,然而,小鼠TNFα是糖基化的,而人TNFα不是。TNFα基因敲除动物对细菌感染的反应有缺陷,其特征是形成有组织的滤泡树突状细胞网络和生发中心的缺陷,缺乏初级B细胞滤泡。

 新闻图片1


二  产品详情

产品货号 BE0058
产品规格 1/5/25/50/100mg
抗体亚型 Rat IgG1
推荐同型对照 InVivoMAb rat IgG1 isotype control, anti-horseradish peroxidase(货号:BE0088
推荐抗体稀释液 InVivoPure™ pH 8.0 Dilution Buffer(货号:IP0080
免疫原 Recombinant mouse TNFα
应用 in vivo TNFα neutralization
in vitro TNFα neutralization、Western blot
产品形式 PBS , pH 8.0 Contains no stabilizers or preservatives
内毒素水平 <2EU/mg (<0.002EU/μg)
纯度 >95% Determined by SDS-PAGE
无菌处理 0.2 μM filtered
生产形式 从组织培养上清液中纯化得到。
纯化形式 Protein G
分子量大小 150 kDa
保存条件 抗体原溶液应保存在4°C条件下,不要冷冻保存。

 

三  已发表文献

用途 已发表文献
in vivo TNFα neutralization Shaabani, N., et al. (2018). “The probacterial effect of type I interferon signaling requires its own negative regulator USP18.” Sci Immunol 3(27).
iin vivo TNFα neutralization Baeyens, A., et al. (2015). “Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context.” J Immunol 194(3): 999-1010
in vivo TNFα neutralization Christensen, A. D., et al. (2015). “Depletion of regulatory T cells in a hapten-induced inflammation model results in prolonged and increased inflammation driven by T cells.” Clin Exp Immunol 179(3): 485-499
in vivo TNFα neutralization Grinberg-Bleyer, Y., et al. (2015). “Cutting edge: NF-kappaB p65 and c-Rel control epidermal development and immune homeostasis in the skin.” J Immunol 194(6): 2472-2476.
in vivo TNFα neutralization Beug, S. T., et al. (2014). “Smac mimetics and innate immune stimuli synergize to promote tumor death.” Nat Biotechnol 32(2): 182-190
in vivo TNFα neutralization DeBerge, M. P., et al. (2014). “Soluble, but not transmembrane, TNF-alpha is required during influenza infection to limit the magnitude of immune responses and the extent of immunopathology.” J Immunol 192(12): 5839-5851. 
in vivo TNFα neutralization Deng, L., et al. (2014). “Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.” J Clin Invest 124(2): 687-695
in vivo TNFα neutralization Maltby, S., et al. (2014). “Production and differentiation of myeloid cells driven by proinflammatory cytokines in response to acute pneumovirus infection in mice.” J Immunol 193(8): 4072-4082
in vivo TNFα neutralization Yoo, J. K. and T. J. Braciale (2014). “IL-21 promotes late activator APC-mediated T follicular helper cell differentiation in experimental pulmonary virus infection.” PLoS One 9(9): e105872.
in vivo TNFα neutralization Dietze, K. K., et al. (2013). “Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads.” PLoS Pathog 9(12): e1003798
in vivo TNFα neutralization Kugler, D. G., et al. (2013). “CD4+ T cells are trigger and target of the glucocorticoid response that prevents lethal immunopathology in toxoplasma infection.” J Exp Med 210(10): 1919-1927
in vivo TNFα neutralization Weinlich, R., et al. (2013). “Protective roles for caspase-8 and cFLIP in adult homeostasis.” Cell Rep 5(2): 340-348. 
in vivo TNFα neutralization Bradley, L. M., et al. (2012). “Matrix metalloprotease 9 mediates neutrophil migration into the airways in response to influenza virus-induced toll-like receptor signaling.” PLoS Pathog 8(4): e1002641
in vivo TNFα neutralization Quezada, S. A., et al. (2010). “Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.” J Exp Med 207(3): 637-650


详情请咨询 BioXcell 中国授权代理-优宁维生物

上海优宁维生物科技股份有限公司

试剂 | 耗材 | 仪器 | 软件 | 定制 | 实验服务 | 供应链

免费热线:4008-168-068

咨询邮箱:info@univ-bio.com

订购商城:www.univ-bio.com

微信公众平台:优宁维抗体专家,欢迎关注!

小优博士(小程序):5大课堂, 让你的科研不再难!

公众号 小程序

上一篇

BioXcell特色产品推荐之:InVivoPlus anti TGF-β

下一篇

肿瘤标志性事件相关信号通路及关键靶点

更多资讯

我的询价